These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 5556742)
21. Developing an effective P & T Committee, Part 2. Abramowitz PW; Godwin HN; Latiolais CJ; McDougal TR; Miller WA; Ravin RL Hosp Formul; 1985 Oct; 20(10):1071-2, 1078-81, 1086 passim. PubMed ID: 10273830 [TBL] [Abstract][Full Text] [Related]
22. [Work of the committee on drug side effects]. Naes K Tidsskr Nor Laegeforen; 1975 Aug; 95(22):1237-8. PubMed ID: 1162664 [No Abstract] [Full Text] [Related]
23. [Create or strengthen the drug committee at a hospital]. Bruneton C Med Trop (Mars); 2006 Dec; 66(6):569-72. PubMed ID: 17286023 [TBL] [Abstract][Full Text] [Related]
24. Achieving rational therapeutics through consensus-based protocols and follow-up. Quintiliani R; Gousse GC; Chow MS Hosp Formul; 1990 Mar; 25(3):283-4, 289-94. PubMed ID: 10103836 [TBL] [Abstract][Full Text] [Related]
25. Can drug utilization help in promoting the more rational use of medicine? Experiences from Western Nepal. Shankar PR; Mishra P; Subish P; Upadhyay DK Pak J Pharm Sci; 2007 Jul; 20(3):243-48. PubMed ID: 17545111 [TBL] [Abstract][Full Text] [Related]
27. Rational drug use (II): Hospital drug and therapeutics committees. Manyemba J; Dzuda C; Nyazema NZ Cent Afr J Med; 2000 Sep; 46(9):256-9. PubMed ID: 11320773 [No Abstract] [Full Text] [Related]
28. Improving pharmacy and therapeutics committee operations. Cohen MR; Klapp D; Miller KB; Shaffer VL; Slotfeldt M; Miller DE Am J Hosp Pharm; 1984 Sep; 41(9):1767-77. PubMed ID: 6496511 [TBL] [Abstract][Full Text] [Related]
29. Adverse drug reactions and the P & T committee. Lipman AG Hosp Formul; 1980 Jul; 15(7):580. PubMed ID: 10247654 [No Abstract] [Full Text] [Related]
33. Implementation of an intravenous potassium policy. Cooper BE Hosp Pharm; 1989 Jun; 24(6):462-4. PubMed ID: 10293974 [TBL] [Abstract][Full Text] [Related]
34. [Hospital essential drugs in Africa. An example of pharmacoeconomic research]. Meillon C; Stum N; Cuisinier-Raynal JC Dakar Med; 1996; Spec No():19-20. PubMed ID: 14520980 [No Abstract] [Full Text] [Related]
35. P & T Committee rises to challenges of the changing healthcare environment. Eybel CE; Pierpaoli PG; Carasiti ME Hosp Formul; 1991 Nov; 26(11):886-8, 890-4. PubMed ID: 10114819 [TBL] [Abstract][Full Text] [Related]
36. The use of tetracycline. J Iowa Med Soc; 1980 Aug; 70(8):333-4, 346. PubMed ID: 7400637 [No Abstract] [Full Text] [Related]
37. Twenty years' experience with drug information centers. Amerson AB; Wallingford DM Am J Hosp Pharm; 1983 Jul; 40(7):1172-8. PubMed ID: 6881155 [TBL] [Abstract][Full Text] [Related]
38. The Drug Spotlight Program. Aagaard GN J Assoc Hosp Med Educ; 1978; 1st Quarter():58-60. PubMed ID: 10307276 [No Abstract] [Full Text] [Related]
39. IV push policy: the economic effects of IV drug administration guidelines. Hughes TE; Suzuki NT Hosp Formul; 1986 Jul; 21(7):793-9, 802. PubMed ID: 10317755 [TBL] [Abstract][Full Text] [Related]
40. Developing an effective P&T Committee, Part I. Abramowitz PW; Godwin HN; Latiolais CJ; McDougal TR; Miller WA; Ravin RL Hosp Formul; 1985 Jul; 20(7):827-8, 837, 841-3 passim. PubMed ID: 10271920 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]